A Phase 1 interventional study of IMC-S118AI in Type 1 Diabetes, Type 1 Diabetes (T1D) and Diabetes Type 1, sponsored by Immunocore Ltd. Not yet recruiting. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Immunocore Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 154 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Immunocore Ltd is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single ascending doses of IMC-S118AI.
Biological: IMC-S118AI
Participants receive multiple ascending doses of IMC-S118AI.
Biological: IMC-S118AI
IMC-S118AI solution for infusion/injection
Number of participants with ≥1 treatment-emergent serious adverse event (SAE)
Time frame: Up to 60 weeks
Number of participants with ≥1 treatment-emergent adverse event (AE)
Time frame: Up to 45 weeks
Number of participants with clinically significant changes in safety laboratory parameters
Time frame: Up to 45 weeks
Number of participants with clinically significant changes in vital signs
Time frame: Up to 45 weeks
Number of participants with clinically significant changes in electrocardiogram (ECG)
Time frame: Up to 45 weeks
Number of participants with dose interruptions, reductions, or discontinuations
Time frame: Up to 21 weeks
Plasma concentration of IMC-S118AI
Time frame: Up to 21 weeks
Number of participants with anti-IMC-S118AI antibody formation
Time frame: Up to 31 weeks
AUC of serum C-peptide after a 2 h MMTT at Week 25
Time frame: Week 25
No study locations are listed for this record.
Start is estimated for Apr 2026; primary completion for Nov 2030, 55 months later.
Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 55 months is above that.
Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Immunocore Ltd